Category Archives: CLSA Home

CLSA Applauds U.S. House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

Today, CLSA issued a statement applauding the Congressional passage of S. 1379, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019, legislation that is key to strengthening our national preparedness and response for public health emergencies and accelerating medical countermeasure research and development. Share links below and more information attached.

Governor Newsom Releases His Revised Budget Plan

On May 9, 2019, Governor Newsom released a revised state budget proposal (known as the “May Revise”) focusing on health care, housing, early childhood, and education. The budget addressed his priorities for the “Healthcare for All” policy agenda, which includes expanding Medi-Cal coverage to young adults regardless of their immigration status.

CLSA & Allied Stakeholders Succeed in Halting Administration’s Final Rule on Six Protected Classes in Medicare Part D

On Thursday, May 16, CLSA’s advocacy paid off when CMS released its final rule and fact sheet. In the final rule, CMS decided to not adopt two proposals which would have allowed Part D plans to exclude a protected class drug from their formularies for multiple years if price-growth exceeded an inflation index as well as if the drug represented a new formulation that is not a significant innovation over the original product.

CLSA Elects Melinda Richter of Johnson & Johnson Innovation – JLABS as New Board Chair, Appoints New Vice Chair, Treasurer

Today, CLSA announced the transitional board appointment of Melinda Richter, Global Head, Johnson & Johnson Innovation – JLABS from Vice Chair to Chair of CLSA’s Board of Directors. Alex Kelly, Executive Vice President, Corporate Affairs and Chief Communications Officer, Allergan, will move into the position of Vice Chair, ceding the role of Treasurer to Jeff Jonker, President and CEO, Ambys Medicines.